AU2015369627A1 - Probiotic organisms for diagnosis, monitoring, and treatment of inflammatory bowel disease - Google Patents

Probiotic organisms for diagnosis, monitoring, and treatment of inflammatory bowel disease Download PDF

Info

Publication number
AU2015369627A1
AU2015369627A1 AU2015369627A AU2015369627A AU2015369627A1 AU 2015369627 A1 AU2015369627 A1 AU 2015369627A1 AU 2015369627 A AU2015369627 A AU 2015369627A AU 2015369627 A AU2015369627 A AU 2015369627A AU 2015369627 A1 AU2015369627 A1 AU 2015369627A1
Authority
AU
Australia
Prior art keywords
cell
promoter
recombinant
molecule
output
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2015369627A
Other languages
English (en)
Inventor
Dean Falb
Vincent ISABELLA
Jonathan Kotula
Timothy Kuan-Ta Lu
Paul Miller
Isaak Elis MUELLER
Jacob Rosenblum RUBENS
Gianluca SELVAGGIO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Synlogic Operating Co Inc
Original Assignee
Massachusetts Institute of Technology
Synlogic Operating Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology, Synlogic Operating Co Inc filed Critical Massachusetts Institute of Technology
Publication of AU2015369627A1 publication Critical patent/AU2015369627A1/en
Assigned to MASSACHUSETTS INSTITUTE OF TECHNOLOGY, SYNLOGIC OPERATING COMPANY, INC. reassignment MASSACHUSETTS INSTITUTE OF TECHNOLOGY Alteration of Name(s) of Applicant(s) under S113 Assignors: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, SYNLOGIC, INC.
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/064—Saccharomycetales, e.g. baker's yeast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Physiology (AREA)
  • Toxicology (AREA)
  • Medical Informatics (AREA)
AU2015369627A 2014-12-22 2015-12-22 Probiotic organisms for diagnosis, monitoring, and treatment of inflammatory bowel disease Abandoned AU2015369627A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462095415P 2014-12-22 2014-12-22
US62/095,415 2014-12-22
PCT/US2015/067435 WO2016106343A1 (en) 2014-12-22 2015-12-22 Probiotic organisms for diagnosis, monitoring, and treatment of inflammatory bowel disease

Publications (1)

Publication Number Publication Date
AU2015369627A1 true AU2015369627A1 (en) 2017-07-06

Family

ID=55273522

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015369627A Abandoned AU2015369627A1 (en) 2014-12-22 2015-12-22 Probiotic organisms for diagnosis, monitoring, and treatment of inflammatory bowel disease

Country Status (6)

Country Link
US (1) US20170360850A1 (https=)
EP (1) EP3237437A1 (https=)
JP (1) JP2018501797A (https=)
AU (1) AU2015369627A1 (https=)
CA (1) CA2971876A1 (https=)
WO (1) WO2016106343A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160206666A1 (en) 2014-12-22 2016-07-21 Synlogic, Inc. Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tighten gut mucosal barrier
US11685925B2 (en) 2015-10-30 2023-06-27 Synlogic Operating Company, Inc. Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
EP3622093A4 (en) * 2017-05-12 2021-05-26 Baylor College of Medicine DEVELOPMENT OF MICROBIAL BIOSENSORS FOR INTESTINAL IGNITION
WO2019047166A1 (en) 2017-09-08 2019-03-14 New Portal Limited NUCLEIC ACID SYSTEMS THAT ALLOW BACTERIA TO SPECIFICALLY TARGET SOLID TUMORS THROUGH GLUCOSE DEPENDENT VIABILITY
WO2019203802A1 (en) 2018-04-17 2019-10-24 Massachusetts Institute Of Technology An ingestible system to monitor gastrointestinal health in situ
JP2022512639A (ja) * 2018-10-09 2022-02-07 セカンド ゲノム インコーポレイテッド 上皮バリア機能障害の治療に有効なタンパク質を送達するためのラクトコッカス・ラクティス発現系
US11926849B2 (en) 2019-03-29 2024-03-12 The General Hospital Corporation Biosensors in human gut organoids
CA3142608A1 (en) 2019-06-04 2020-12-10 Cocoon Biotech Inc. Silk-based products, formulations, and methods of use
WO2021048172A2 (en) 2019-09-09 2021-03-18 River Stone Biotech Aps Delivery vehicle for in situ delivering of pharmaceutical agents
WO2022006748A1 (en) 2020-07-07 2022-01-13 New Portal Limited Genetically engineered live bacteria and methods of constructing the same
CN112961872B (zh) * 2021-02-25 2022-09-30 上海健康医学院 益生菌嵌合传感器及其构建方法和应用
EP4508236A4 (en) * 2022-04-13 2026-04-15 Baylor College Medicine Bacterial biosensors for the diagnosis and treatment of inflammation
WO2025233942A1 (en) * 2024-05-07 2025-11-13 Technion Research & Development Foundation Limited Synthetic microbiome consortia and use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0501540D0 (en) * 2005-01-25 2005-03-02 Univ Leeds Controlled production and delivery of biologically active agents by gut bacteria
CN105144204B (zh) * 2012-12-13 2018-02-27 麻省理工学院 基于重组酶的逻辑与存储系统

Also Published As

Publication number Publication date
US20170360850A1 (en) 2017-12-21
WO2016106343A1 (en) 2016-06-30
CA2971876A1 (en) 2016-06-30
EP3237437A1 (en) 2017-11-01
JP2018501797A (ja) 2018-01-25
WO2016106343A8 (en) 2016-08-11

Similar Documents

Publication Publication Date Title
US20170360850A1 (en) Probiotic organisms for diagnosis, monitoring, and treatment of inflammatory bowel disease
Mahdizade Ari et al. Genetically engineered microorganisms and their impact on human health
Aggarwal et al. Engineering probiotics for therapeutic applications: recent examples and translational outlook
AU2017272721B2 (en) Novel genetically engineered vaccinia viruses
Bober et al. Synthetic biology approaches to engineer probiotics and members of the human microbiota for biomedical applications
RU2644346C2 (ru) Система полицистронной экспрессии для бактерий
KR20170121291A (ko) 감소된 창자 염증 및/또는 강화된 창자 점막 장벽으로부터 이익을 얻는 질병을 치료하기 위해 공학처리된 박테리아
US9228191B2 (en) Transfection vector
KR20210148182A (ko) 클로스트리디움 디피실레 감염 및 재발성 감염 관리를 위한 조작된 디스바이오시스-센싱 프로바이오틱
US20210115455A1 (en) Compositions and methods for regulated gene expression
Daifalla et al. Commensal Streptococcus mitis is a unique vector for oral mucosal vaccination
Xuan et al. Oral administration of mice with cell extracts of recombinant Lactococcus lactis IL1403 expressing mouse receptor activator of NF-kB ligand (RANKL)
Gopal et al. C-terminal domain of CagX is responsible for its interaction with CagT protein of Helicobacter pylori type IV secretion system
CA2801729A1 (en) Compositions for and methods of activating guanylyl cyclase c
JP2025538196A (ja) 組換えテールスパイクタンパク質との合成ファージおよび関連する方法
Park et al. A safe and versatile minicell platform derived from Lactiplantibacillus plantarum for biotechnological applications
Kim et al. Transcription factor-based biosensors and their application in microbiome engineering
JP2007530034A (ja) 新規のマンノース特異的アドヘシンとその使用
WO2019067447A2 (en) COMPOSITIONS COMPRISING A CHIMERIC BACTERIAL SURFACE LAYER PROTEIN AND METHODS OF USE
Kurt Engineering of Probiotic Saccharomyces boulardii as a Host for Living Therapeutic Applications
Parker The Investigation of SliP in Campylobacter jejuni as an Intracellularly Secreted Protein
US20190359695A1 (en) Recombinant expression systems and products
WO2024249677A1 (en) Compositions and methods for increasing secretion of molecules
Erridge The search for Lactobacillus proteins that bind to host targets: a thesis presented in partial fulfilment of the requirements for the degree of Master of Science in Microbiology at Massey University, Turitea, New Zealand
Erridge The search for Lactobacillus proteins that bind to host targets

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: SYNLOGIC OPERATING COMPANY, INC.

Free format text: FORMER NAME(S): MASSACHUSETTS INSTITUTE OF TECHNOLOGY; SYNLOGIC, INC.

Owner name: MASSACHUSETTS INSTITUTE OF TECHNOLOGY

Free format text: FORMER NAME(S): MASSACHUSETTS INSTITUTE OF TECHNOLOGY; SYNLOGIC, INC.

MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period